Drugs / SAR444881
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04717375 | Apr 2021 → Jul 2025 | cancer | Sanofi | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06651593 | Jul 2025 → Sep 2028 expected | cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR444881 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04717375 ↗ |
| Route | Intravenous | “Given by IV” NCT06651593 ↗ |